Humacyte (HUMA) Competitors

Humacyte logo
$0.50 -0.04 (-7.27%)
Closing price 04:00 PM Eastern
Extended Trading
$0.52 +0.01 (+2.79%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HUMA vs. YDES, MNPR, ARVN, MDXG, and EPRX

Should you buy Humacyte stock or one of its competitors? Humacyte's main competitors and comparable companies include YD Bio (YDES), Monopar Therapeutics (MNPR), Arvinas (ARVN), MiMedx Group (MDXG), and Eupraxia Pharmaceuticals (EPRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Humacyte compare to YD Bio?

YD Bio (NASDAQ:YDES) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

44.7% of Humacyte shares are held by institutional investors. 3.1% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

YD Bio has higher earnings, but lower revenue than Humacyte.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
YD BioN/AN/AN/AN/AN/A
Humacyte$2.04M73.58-$40.83M-$0.44N/A

Humacyte has a consensus price target of $4.48, suggesting a potential upside of 729.40%. Given Humacyte's stronger consensus rating and higher probable upside, analysts plainly believe Humacyte is more favorable than YD Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
YD Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Humacyte
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

YD Bio has a net margin of 0.00% compared to Humacyte's net margin of -3,955.05%. YD Bio's return on equity of 0.00% beat Humacyte's return on equity.

Company Net Margins Return on Equity Return on Assets
YD BioN/A N/A N/A
Humacyte -3,955.05%-612.88%-80.03%

YD Bio has a beta of -1.2, indicating that its share price is 220% less volatile than the broader market. Comparatively, Humacyte has a beta of 2.64, indicating that its share price is 164% more volatile than the broader market.

In the previous week, Humacyte had 25 more articles in the media than YD Bio. MarketBeat recorded 29 mentions for Humacyte and 4 mentions for YD Bio. YD Bio's average media sentiment score of 0.62 beat Humacyte's score of 0.28 indicating that YD Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
YD Bio
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Humacyte
3 Very Positive mention(s)
6 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Humacyte beats YD Bio on 8 of the 12 factors compared between the two stocks.

How does Humacyte compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

In the previous week, Humacyte had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 29 mentions for Humacyte and 28 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.53 beat Humacyte's score of 0.28 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Monopar Therapeutics
5 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Humacyte
3 Very Positive mention(s)
6 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Monopar Therapeutics has a net margin of 0.00% compared to Humacyte's net margin of -3,955.05%. Monopar Therapeutics' return on equity of -15.30% beat Humacyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Monopar TherapeuticsN/A -15.30% -14.94%
Humacyte -3,955.05%-612.88%-80.03%

Monopar Therapeutics has higher earnings, but lower revenue than Humacyte. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monopar TherapeuticsN/AN/A-$13.72M-$2.41N/A
Humacyte$2.04M73.58-$40.83M-$0.44N/A

Monopar Therapeutics presently has a consensus price target of $123.13, suggesting a potential upside of 71.08%. Humacyte has a consensus price target of $4.48, suggesting a potential upside of 729.40%. Given Humacyte's higher probable upside, analysts plainly believe Humacyte is more favorable than Monopar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monopar Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Humacyte
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by insiders. Comparatively, 3.1% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Monopar Therapeutics has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.64, indicating that its stock price is 164% more volatile than the broader market.

Summary

Monopar Therapeutics and Humacyte tied by winning 6 of the 12 factors compared between the two stocks.

How does Humacyte compare to Arvinas?

Arvinas (NASDAQ:ARVN) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Arvinas has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.64, indicating that its share price is 164% more volatile than the broader market.

Arvinas presently has a consensus target price of $15.18, indicating a potential upside of 124.25%. Humacyte has a consensus target price of $4.48, indicating a potential upside of 729.40%. Given Humacyte's stronger consensus rating and higher probable upside, analysts plainly believe Humacyte is more favorable than Arvinas.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arvinas
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50
Humacyte
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

Humacyte has lower revenue, but higher earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arvinas$262.60M1.69-$80.80M-$0.24N/A
Humacyte$2.04M73.58-$40.83M-$0.44N/A

In the previous week, Humacyte had 25 more articles in the media than Arvinas. MarketBeat recorded 29 mentions for Humacyte and 4 mentions for Arvinas. Humacyte's average media sentiment score of 0.28 beat Arvinas' score of -0.14 indicating that Humacyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arvinas
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Humacyte
3 Very Positive mention(s)
6 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Arvinas has a net margin of -3.45% compared to Humacyte's net margin of -3,955.05%. Arvinas' return on equity of -2.00% beat Humacyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Arvinas-3.45% -2.00% -1.43%
Humacyte -3,955.05%-612.88%-80.03%

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 7.3% of Arvinas shares are owned by company insiders. Comparatively, 3.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Arvinas and Humacyte tied by winning 7 of the 14 factors compared between the two stocks.

How does Humacyte compare to MiMedx Group?

MiMedx Group (NASDAQ:MDXG) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

MiMedx Group currently has a consensus target price of $8.14, indicating a potential upside of 156.06%. Humacyte has a consensus target price of $4.48, indicating a potential upside of 729.40%. Given Humacyte's higher probable upside, analysts clearly believe Humacyte is more favorable than MiMedx Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiMedx Group
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Humacyte
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

MiMedx Group has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.64, suggesting that its share price is 164% more volatile than the broader market.

In the previous week, Humacyte had 25 more articles in the media than MiMedx Group. MarketBeat recorded 29 mentions for Humacyte and 4 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.24 beat Humacyte's score of 0.28 indicating that MiMedx Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiMedx Group
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Humacyte
3 Very Positive mention(s)
6 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

MiMedx Group has higher revenue and earnings than Humacyte. MiMedx Group is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiMedx Group$418.63M1.11$48.58M-$0.13N/A
Humacyte$2.04M73.58-$40.83M-$0.44N/A

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by insiders. Comparatively, 3.1% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MiMedx Group has a net margin of -6.32% compared to Humacyte's net margin of -3,955.05%. MiMedx Group's return on equity of 2.39% beat Humacyte's return on equity.

Company Net Margins Return on Equity Return on Assets
MiMedx Group-6.32% 2.39% 1.85%
Humacyte -3,955.05%-612.88%-80.03%

Summary

MiMedx Group beats Humacyte on 9 of the 14 factors compared between the two stocks.

How does Humacyte compare to Eupraxia Pharmaceuticals?

Humacyte (NASDAQ:HUMA) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Humacyte presently has a consensus price target of $4.48, indicating a potential upside of 729.40%. Eupraxia Pharmaceuticals has a consensus price target of $18.00, indicating a potential upside of 145.23%. Given Humacyte's higher probable upside, research analysts plainly believe Humacyte is more favorable than Eupraxia Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Humacyte
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Eupraxia Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Humacyte's net margin of -3,955.05%. Eupraxia Pharmaceuticals' return on equity of -67.78% beat Humacyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Humacyte-3,955.05% -612.88% -80.03%
Eupraxia Pharmaceuticals N/A -67.78%-46.73%

Humacyte has a beta of 2.64, meaning that its stock price is 164% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

44.7% of Humacyte shares are owned by institutional investors. 3.1% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Humacyte. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Humacyte$2.04M73.58-$40.83M-$0.44N/A
Eupraxia PharmaceuticalsN/AN/A-$38.58M-$1.06N/A

In the previous week, Humacyte had 6 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 29 mentions for Humacyte and 23 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.43 beat Humacyte's score of 0.28 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Humacyte
3 Very Positive mention(s)
6 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Eupraxia Pharmaceuticals
3 Very Positive mention(s)
3 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Eupraxia Pharmaceuticals beats Humacyte on 8 of the 15 factors compared between the two stocks.

Get Humacyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HUMA vs. The Competition

MetricHumacyteBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$150.09M$4.06B$7.82B$11.74B
Dividend YieldN/A3.63%2.47%4.46%
P/E RatioN/A27.4232.3226.73
Price / Sales68.2216.068.565.71
Price / CashN/A22.9521.0121.90
Price / Book7.164.184.463.72
Net Income-$40.83M-$24.15M$3.52B$393.10M
7 Day Performance-15.08%-7.25%-5.47%-4.73%
1 Month Performance16.78%-5.98%-4.57%-7.14%
1 Year Performance-55.66%-7.72%-1.79%-7.51%

Humacyte Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HUMA
Humacyte
3.2768 of 5 stars
$0.50
-7.3%
$4.48
+794.5%
-56.1%$150.09M$2.04MN/A184
YDES
YD Bio
1.3723 of 5 stars
$6.71
+12.4%
N/AN/A$491.98MN/AN/A14
MNPR
Monopar Therapeutics
2.5813 of 5 stars
$73.75
+3.3%
$122.78
+66.5%
-7.7%$488.71MN/AN/A22
ARVN
Arvinas
2.3308 of 5 stars
$6.76
+5.5%
$15.18
+124.6%
-36.0%$485.90M$262.60MN/A246
MDXG
MiMedx Group
2.5932 of 5 stars
$3.32
+0.3%
$8.14
+145.3%
-56.9%$466.96M$418.63MN/A808

Related Companies and Tools


This page (NASDAQ:HUMA) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners